EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease

Eleonora M Vromen, Senne B Lageman iD, Johan Gobom, Rik van der Kant, Valerija Dobricic, Lars Bertram, Johannes Streffer, Simon Lovestone, Stephanie J B Vos, Mikel Tainta, Yvonne Freund-Levi, Lutz Frölich und 15 weitere

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.10.2025. Verfasst von Eleonora M Vromen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Apolipoproteins E, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Alzheimer Nederland and Stichting VUmc, Pasman stichting, Research Council of Norway INFRASTRUKTUR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The apolipoprotein E ( APOE ) gene includes the strongest protective (ε2) and risk (ε4) variants for sporadic Alzheimer's disease (AD), but underlying mechanisms remain unclear. We studied APOE genotype effects on the cerebrospinal fluid (CSF) proteome. METHODS Using untargeted tandem mass tag mass spectrometry, we analyzed CSF from 227 cognitively normal (CN) controls (A–T–), 165 CN A+, and 177 individuals with mild cognitive impairment (MCI A+) from two large cohorts. We compared protein levels across APOE genotypes using linear regression and characterized biological pathways. RESULTS Five hundred forty‐nine of 978 proteins (56%) differed between ε2/ε3 ( n = 32 individuals) or ε4 carriers ( n = 181 individuals) and ε3/ε3 controls. ε2/ε3 controls showed the most differences, with higher levels of 280 proteins enriched for neuronal plasticity. ε4 carrier controls showed increased proteins linked to blood–brain barrier dysfunction, and A+ ε4 carriers were related to glucose metabolism. DISCUSSION Combining two cohorts enabled analysis of the rare APOE ε2 genotype, suggesting protective effects may occur through improved neuronal plasticity. Highlights Apolipoprotein E ( APOE ) genotypes show distinct cerebrospinal fluid proteomic mechanisms in early Alzheimer's disease (AD). Combining cohorts enabled analysis of rare APOE ε2–associated protection in AD. The rare ε2 genotype may confer protection through improved neuronal plasticity. APOE ε4 carriers show increased blood–brain barrier dysfunction and glucose metabolism. These findings offer new insights into genotype‐specific mechanisms in early AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseApolipoproteins ECognitive DysfunctionHumansMaleFemaleProteomicsAgedGenotypeMiddle AgedCohort StudiesAged, 80 and overGenetic Predisposition to DiseaseBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseapolipoprotein Ecerebrospinal fluidcognitively normalmild cognitive impairmentprotectionproteomicsrisk

Substanzen

Apolipoproteins EBiomarkersApoE protein, human

Autor:innen und Institutionen

  • Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
  • Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany.
  • Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Antwerp, Belgium.

ORCID-Profile: Senne B Lageman

Förderung

  • Stichting Alzheimer Nederland and Stichting VUmc
  • Pasman stichting
  • Research Council of Norway INFRASTRUKTUR
  • Innovative Medicines Initiative Joint Undertaking
  • European Union's Seventh Framework Program
  • ZonMw Memorabel
  • ZonMW VIDI
  • EPND

Zitieren

APA

Vromen, E. M., Lageman, S. B., Gobom, J., van der Kant, R., Dobricic, V., Bertram, L., Streffer, J., Lovestone, S., Vos, S. J. B., Tainta, M., Freund-Levi, Y., Frölich, L., Popp, J., Peyratout, G., Tsolaki, M., Verhey, F., Vandenberghe, R., Schaeverbeke, J., Blennow, K., …, & Tijms, B. (2025). Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70738

Vancouver

Vromen EM, Lageman SB, Gobom J, van der Kant R, Dobricic V, Bertram L, et al. Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70738

BibTeX
@article{Vromen2025,
  author = {Vromen, Eleonora M and Lageman, Senne B and Gobom, Johan and van der Kant, Rik and Dobricic, Valerija and Bertram, Lars and Streffer, Johannes and Lovestone, Simon and Vos, Stephanie J B and Tainta, Mikel and Freund-Levi, Yvonne and Frölich, Lutz and Popp, Julius and Peyratout, Gwendoline and Tsolaki, Magda and Verhey, Frans and Vandenberghe, Rik and Schaeverbeke, Jolien and Blennow, Kaj and van der Lee, Sven J and Scheltens, Philip and Pijnenburg, Yolande A L and van der Flier, Wiesje M and Teunissen, Charlotte E and Zetterberg, Henrik and Visser, Pieter Jelle and Tijms, Betty},
  title = {Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70738}
}
Kostenlos starten →